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Purpose: The researchers conducted a randomized, multicenter, open-label, phase 3 
study of patients with recurrent GBM who had failed front-line therapy to evaluate the 
anti-tumor effect of imatinib in combination with HU. This study was designed to 
determine whether imatinib has sufficient synergistic anti-tumor activity in combination 
with HU in comparison to single-agent treatment with HU for recurrent GBM.  
Patients and Methods: The target population consisted of patients with previously 
treated, confirmed progressive GBM, an Eastern Cooperative Oncology Group 
performance status of 0-2 with completed surgical treatment and irradiation therapy or 
first-line chemotherapy; if first-line chemotherapy did not contain TMZ, a second 
completed chemotherapy was required.  
Results: The primary efficacy parameter was progression-free survival (PFS) during the 
study. The primary comparison of combination therapy versus monotherapy for PFS is 
not significant at the 5% level (adjusted P = 0.564). The hazard ratio (HR) is in favor of 
the combination therapy, but the size of the effect is very small (adjusted HR = 0.925) 
and not clinically relevant. The median PFS for the combination arm was low at 6.3 
weeks and similar to the median PFS in the monotherapy arm (6.1 weeks). The 6-month 
PFS between the two treatment groups was very similar (5.3% in the combination arm 
versus 6.6% in the monotherapy arm). 
Conclusion: Overall, no clinically meaningful differences were found between the 2 
treatment arms, and the primary study end point was not met. Among patients receiving 
imatinib, no safety issues arose that were either previously unknown or not expected as a 
consequence of the disease. 
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INTRODUCTION 
Glioblastoma (GBM) (WHO grade IV) is a high-grade malignancy of the CNS with a 
poor prognosis. The rate of progression-free survival (PFS) at 1 year is approximately 
40%.1 Surgical resection followed by radiotherapy and concomitant temozolomide 
(TMZ), followed by regular TMZ for 6 months is the standard of care. Although PFS can 
be prolonged by approximately 3 to 6 months, median overall survival (OS) remains 
unsatisfactory at 15.6 months and recurrence rates are high.1  
Treatment at disease progression includes resection, if possible, and/or further 
chemotherapy; however, outcomes remain poor. A variety of new approaches have been 
tested in the recurrent setting, including novel chemotherapy agents, chemotherapy 
combinations, and, more recently, agents targeting epidermal growth factor receptor 
(EGFR), platelet-derived growth factor receptors (PDGFR), and vascular endothelial 
growth factor receptor (VEGFR).2 In GBM, EGFR and PDGFR are amplified in 
approximately 50%2 and 21% of patients, respectively.3 All attempts to prolong the 
length of PFS and OS using biological agents such as thalidomide, melatonin, cis/trans 
retinoic acids, or gene therapy did not significantly improve prognosis. 
Imatinib has limited single-agent activity in recurrent GBM.4,5 Among other activities, 
imatinib is known to inhibit the activity of PDGFR and c-KIT receptors. Hydroxyurea 
(HU) is thought to promote the penetration of drugs across the blood-brain-barrier 
(BBB), as well as induce the loss of amplified genes, including the EGFR gene.6 Because 
PDGFR, c-KIT, and EGFR overexpression is seen in GBM6-11 and HU can increase 
permeability of the BBB, combining the drugs was considered a treatment option worth 
investigating. Results of a pilot study of 30 patients suggested that a combination of HU 
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and imatinib is active in recurrent GBM,12-14 and the study was soon repeated in study 
BUS218.15  
 
PATIENTS AND METHODS 
The present study was a multicenter, 2-arm, open-label, phase 3 study for patients with 
recurrent GBM. The primary objective was to evaluate whether a combination of 
imatinib and HU was superior to HU alone in prolonging PFS. Secondary objectives 
included PFS at 12 months, overall response, duration of response, safety, and OS.  
Adult patients with a histologically confirmed GBM, measurable disease, and an Eastern 
Cooperative Oncology Group (ECOG) performance score < 2 who had previously 
undergone surgery and received radiotherapy and prior chemotherapy were eligible for 
randomization. Patients on steroids were required to have been on a stable dose for ≥ 5 
days. Patients at excessive risk of intracranial hemorrhagic events or with evidence of 
intra-tumoral hemorrhage at baseline scan were not eligible. Patients were required to 
have adequate renal, hepatic, and hematologic function. 
Following previous research, 16,17 patients were stratified according to their receipt of 
EIAEDs or not, however the dose of imatinib was not altered per stratification.  The 
choice of 1000 mg/d HU was based on reported efficacy of the single agent in patients 
with recurrent or unresectable meningioma.18 
The study included 240 patients randomized to receive 1500 mg/d of HU (500 mg 3 
times daily) or imatinib 600 mg/d in combination with 1000 mg/d of HU (500 mg twice 
daily) (Figure 1). Following randomization, patients received treatment until progression 
or trial withdrawal. The protocol scheduled an evaluation using the Macdonald criteria19 
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to be performed every 6 weeks from treatment start. On progression, patients with good 
performance status who were receiving HU alone were permitted to switch to the 
combination arm. For patients progressing on the combination arm, the dose of imatinib 
was escalated to 800 mg/d while the dose of HU remained unchanged.  
In the event of further progression, patients receiving 800 mg/d of imatinib were 
withdrawn from the trial. Only the first progression on treatment was evaluated for the 
primary end point.  
All MRI scans and neurologic and steroid information were evaluated at the local study 
sites in addition to a review by a blinded central independent reviewer (CIR) (Dr Greg 
Sorensen, Massachusetts General Hospital, USA), applying the Macdonald criteria for 
tumor response.19 Blinded CIR data were used for the primary analyses on an intent to 
treat (ITT) basis, and sensitivity analyses were performed to compare the CIR results to 
the results documented at the sites.  
Statistical Analyses 
The primary objective of the study was to demonstrate PFS superiority of imatinib in 
combination with HU over HU monotherapy. The null hypothesis stated that the PFS of 
the 2 treatment groups were equivalent. The alternative hypothesis stated that the PFS of 
either group was prolonged. A median PFS was expected to be 16 and 10 weeks for the 
combination and monotherapy groups, respectively. Based on a 90% power to exceed 
stopping boundaries defined for the interim analysis, an estimated 204 events 
(progression, death) were needed. Therefore, 240 patients were recruited to allow for 
premature withdrawals. 
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In the current trial, progressive disease (PD) was defined as any of the following: ≥ 25% 
increase in size of the sum of the products of the largest perpendicular diameters; 
appearance of new lesions; or neurologic progression alone. Complete response, partial 
response, stable disease (SD), or not assessable were alternative response evaluations at 
each visit. All evaluations considered the steroid and neurologic status of patients, in 
addition to existing or new lesions. The primary analysis was conducted on all 
randomized patients.  
PFS was defined as the time from randomization to the first documented progression or 
death. Patients alive and without progression were considered to be censored at the time 
of the last available visit assessment. PFS rates were calculated using the Kaplan-Meier 
method, ignoring strata. Hazard ratios (HR) and the associated P values were derived 
from a Cox proportional hazards model stratified for EIAED use (yes, no) and ECOG 
status (<2, ≥ 2). The HR indicates the effect of combination therapy or monotherapy, and 
an HR <1 favors combination therapy. 
Safety assessments consisted of recording adverse events (AEs) and serious adverse 
events (SAEs), with severity and drug relationship according to NCI Common Toxicity 
Criteria Version 3.20 Regular monitoring of hematology and blood chemistry, vital signs, 
and physical condition also was performed.  
 
RESULTS 
Between October 2004 and July 2006, 240 patients from 19 institutions in 4 countries 
were randomized equally to receive HU alone (n = 120) or HU plus imatinib (n = 120). 
The characteristics of the patients were balanced between the two arms at baseline (Table 
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1). Overall, the median age was 51 years, there was a slight female predominance in the 
combination arm, and 23% of patients were ECOG performance status 2. The median 
time from initial diagnosis was 12 months in both arms. No significant differences 
existed between the 2 arms regarding age, performance status, time from initial diagnosis, 
use of EIAEDs, and prior anti-cancer therapy. Approximately 40% of patients had 
received multiple chemotherapy regimens prior to study entry, and some had undergone 
multiple resections. This extensive prior treatment could indicate difficulty to establish 
control over the tumor growth, or alternatively, could be a result of patients developing 
GBM through advancement of previously better differentiated gliomas. As GBM can 
quickly result in lethal outcomes, many patients are prevented from receiving multiple 
treatment regimens. 
Patients (N = 240) were randomized in a 1:1 ratio, with 118 patients on each arm starting 
treatment (Table 2). At the time of data cutoff for the analysis (October 27, 2006), 7 
patients on combination therapy (5.8%) and 14 (11.7%) on HU monotherapy were still on 
treatment. The majority of discontinuations were a result of disease progression, 
diagnosed by objective identification using follow-up MRI scan or were suspected on 
clinical grounds (eg, deteriorating neurologic state or performance status). AEs were 
responsible for discontinuation of study medication in 18 (15%) patients on combination 
therapy and 20 (16.7%) on monotherapy, respectively.  
Primary Efficacy Results 
No significant differences in PFS rates were found between combination therapy and 
monotherapy following CIR at the 5% level (adjusted P = 0.564) (Table 3, Figure 2). 
The HR of 0.925 (95% CI, 0.709-1.206) favored combination therapy but was not 
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clinically meaningful. The median PFS for the two treatment arms was 6.3 and 6.1 weeks 
for the combination versus monotherapy arms, respectively. The 6-month PFS rates were 
5.3% and 6.6%, respectively.  
Of note is the high number of patients who were given an assessment of PD based on 
neurologic assessment or steroid use alone. Given time, these patients probably would 
have been assessed with PD by MRI, but their early censoring in this manner would have 
adversely affected the PFS calculations. This is discussed further in the section on 
sensitivity analyses. 
 
Secondary Efficacy Results 
Figure 3 shows the OS of the ITT population but does not include patients who 
progressed while on monotherapy before switching to the combination arm or patients 
randomized to combination therapy who were then treated with a higher dose of imatinib.  
The HR for OS (0.920) was similar to that observed for the primary PFS analysis (0.925). 
The estimate is slightly in favor of the combination therapy arm. The median time to 
death for the combination arm was 20.6 weeks and is similar to the median time to death 
in the monotherapy arm (19.3 weeks). The 6-month OS rates in the two treatment groups 
also were similar: 39.9% in the combination arm and 36.7% in the monotherapy arm.  
CIR data showed 2 confirmed responders in the combination therapy arm and 1 in the 
monotherapy arm. The percentage of patients with a best overall response of SD or better 
(complete response plus partial response plus SD) was similar for each treatment group at 
approximately 25%. PD or death was estimated for 67.5% of patients, and 7% were not 
assessable. There were no significant differences between treatment groups. 
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Figure 4 shows the Kaplan-Meier estimates of PFS by the local investigators. The HR, 
based on local assessments for PFS (0.672), varies from the main analysis (0.894). 




Disease progression was the most frequent cause of death during the study and accounted 
for 90% and 85% of deaths in the combination and monotherapy arms, respectively 
(Table 4). Other causes of death included pneumonia, pulmonary embolism, and sepsis, 
all of which were not unexpected for patients with recurrent GBM.  
The rates of AEs leading to discontinuation were similar in both treatment groups (16% 
versus 18% in the monotherapy and combination therapy groups, respectively). The only 
AEs leading to discontinuation to occur in more than 2% of patients in any treatment 
group were general physical health deterioration (3.4% on combination therapy, 5.1% on 
monotherapy) and pneumonia (2.5% on combination therapy). The majority of AEs that 
led to discontinuation were considered a consequence of disease progression.  
Table 5 reports grade 3-4 AEs that occurred in more than 5% of patients in any group. 
Both treatment arms reported similar AEs, and no difference was seen in the combination 
arm when reviewing patients before and after crossover. Headache, fatigue, nausea, 
peripheral edema, and thrombocytopenia were the most frequently observed AEs. Most 
were associated with the disease, and their incidence was as expected. The SAEs 
observed were expected for this indication and class of study drug. When the trial data 
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were compared to previous experience with imatinib, no new safety concerns were 
identified. The use of imatinib and HU appears to be well tolerated. 
 
Sensitivity Analyses 
Originally, the CIR was not included in the study design and setup. It was suspected that 
a difference between local and centrally reviewed results may exist. Several preplanned 
sensitivity analyses were included, such as the impact of including and excluding steroid 
and neurologic data on the response determination; the timing of recruitment to the study 
(later amendments had increasingly strict criteria on inclusion); censoring according to 
the previous assessment (as opposed to time of data cutoff); the impact of results from 
recruiting sites that recruited significantly more patients (approximately 60 patients, 
compared to 15-20 patients at other sites) on the overall results; and whether PD was 
reported at the time of crossover or imatinib increase.  
Seven of the 8 preplanned sensitivity analyses on PFS showed no difference between the 
2 treatment groups. The exception was an analysis heavily influenced by subjective 
judgments during the local review for all sites that showed a significant improvement for 
patients in the combination therapy arm (median PFS, 9.4 weeks; 6-month PFS, 11.5%, P 
= 0.004). When comparing the best overall response results of patients on combination 
therapy versus monotherapy, the local site results were similar to the results of the CIR of 
only the MRI results; the 6-month and median PFS rates were not matched.  
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This study shows no PFS benefit by adding imatinib to HU in patients with recurrent 
GBM. The median PFS was 6.3 and 6.1 weeks for imatinib plus HU versus HU alone, 
respectively. The 6-month PFS rates were 5.3% and 6.6% for the 2 groups, respectively. 
Sensitivity analyses highlighted a difference in interpretation between local and CIR 
assessments, but this could not be attributed to a single influencing factor. The 6-month 
OS was calculated as 39.9% and 36.7% in the combination and monotherapy arms, 
respectively. No new safety concerns were identified for either treatment group. 
Direct comparison of the study results to historical data is difficult. Of note is that the 
exact criteria of GBM assessment across trials vary considerably between publications, 
mostly in the way neurologic and steroid information are used in determining 
progression. For example, both Brada21 and Yung22 scheduled assessments by MRI every 
8 weeks (compared to 6 weeks in the current trial). In addition, it is not clear from their 
publications how neurologic assessments or steroid use affected progression events.  
The primary analysis of PFS ignores missing assessments or long gaps prior to PD or 
death. This was the most conservative approach; including such assessments would have 
biased the results by censoring an event (progression, death) later than it actually 
occurred, simply because information was unavailable any earlier. However, various 
sensitivity analyses address the impact of this and other analytic assumptions. These 
sensitivity analyses were important to review the robustness of the primary analysis 
conclusions; however, they should still be interpreted with caution because of the 
following: 
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 The analysis may include an element of “informative censoring,” meaning that at a 
particular time point the censored patients may in general be closer to progression 
than the patients who continue to be followed up. The usual impact is an increase in 
the median and 6-month PFS rate estimate, which affects comparisons with historical 
results.  
 When patients were assessed as having PD at the local site, investigators adjusted 
treatment by increasing the dose of imatinib or crossing the patient over. If the PD at 
the local site was not a PD according to the MRI data alone (as assessed by the CIR), 
then any comparison between the monotherapy and combination therapy arms could 
be affected by the additional crossover combination treatment in the monotherapy 
arm. If this additional therapy has an impact, the treatment groups’ results may be 
more similar with respect to PFS based on MRI alone. 
 GBM is a rapidly progressing disease, and increasing the dexamethasone dose as a 
result of worsening neurologic symptoms is frequent until disease stabilization is 
achieved. In pilot studies,14,16 imatinib plus HU did not achieve a significant objective 
response rate but a substantial rate of SD was seen within the first 2 months of 
treatment. Therefore, neurologic status and steroid dose might not be appropriate to 
define PD within the first 2 months after randomization, especially if stabilization of 
clinical symptoms can be achieved later while the tumor burden on MRI scan remains 
unchanged. 
 As both treatment groups have the potential to benefit from imatinib exposure, any 
survival effect seen by comparing the treatments is diluted.  
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In the current study, a number of potential confounding factors may have resulted in an 
underestimation of efficacy. 
Progressing GBM usually is accompanied by substantial brain edema. Imatinib may 
increase the likelihood of edema while simultaneously inhibiting tumor growth. 
Adjusting the steroid dose is used to reduce brain edema, regardless of the etiology of the 
edema. In the current trial, any increase in steroid dose automatically led to the 
classification of PD, regardless of when it happened. The tumor evaluation criteria did 
not optimally reflect the above described practice among neuro-oncologists, resulting in a 
discrepancy between local and CIR results: namely, patients classified as PD by CIR 
when they were assessed as SD locally. Many patients with PD were defined by either 
neurologic worsening or steroid increase, and many of these were defined early during 
patients’ treatment (ie, within the first 6 weeks). Patients’ continuation on the study was 
determined locally, not according to CIR, which was obtained primarily retrospectively. 
Subsequently, many patients classified as PD by CIR continued to receive medication 
after the first 6 weeks of treatment because they were classified locally as SD. 
The differences between CIR and local responses were consistent across all sites, so 
although investigator bias cannot be fully excluded, it could hardly be the sole reason for 
the difference. The nature of the GBM progression would mean that any drug, whether 
cytostatic or cytotoxic, would take time to slow the advancement of the disease and even 
more so to start reversing its course. The local responses suggest an apparent time delay 
between the start of treatment and stabilization of tumor proliferation. 
Evaluating the disease differently during the first 2 to 3 months would not account for all 
disease progressions but rather would allow time for a stabilization to be achieved, both 
Dreseman Imatinib and Hydroxyurea in Glioblastoma.JCO_22May08 .doc 
Imatinib and Hydroxyurea or May 19, 2008 
Hydroxyurea in Glioblastoma Patients  
15
symptomatically and a neurologically. By adjusting the steroid dose as required within 
the first few months, without any dose increase to result in a tumor assessment of PD, 
brain edema could be adequately controlled. This in turn would permit assessment of the 
study drug’s performance in stabilizing or reducing tumor burden, not only on its impact 
in controlling edema.  
 
CONCLUSION 
Overall, according to the strict Macdonald criteria,19 no clinically meaningful differences 
were found in median PFS between the 2 treatment arms. OS and PFS at 6 and 12 months 
were generally similar to benchmarks for the treatment outcomes of patients treated for 
recurrent progressing GBM. No safety issues arose for patients receiving imatinib that 
were either previously unknown or not expected as a consequence of the disease. 
A distinct difference between CIR and local evaluations were observed. A correlation 
between central MRI evaluation and investigator responses during the course of the trial 
was apparent, suggesting differences in the application of the Macdonald criteria. The 
nature of progressive GBM might render the Macdonald criteria not specific enough for 
determining a difference between medications within the first 6 to 8 weeks of treatment.  
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Table 1. Patient Demographics and Disease Characteristics   
 Imatinib + 
Hydroxyurea Hydroxyurea Total 
Characteristic (n = 120) (n = 120) (N = 240) 
Age, years    
Mean 52.1 50.2 51.2 
SD 11.3 11.4 11.4 
Median 52.0 51.0 51.0 
Range 26-73 19-73 19-73 
Age group, n (%)    
18-34 years 9 (7.5) 14 (11.7) 23 (9.6) 
35-49 years 45 (37.5) 40 (33.3) 85 (35.4) 
50-64 years 47 (39.2) 55 (45.8) 102 (42.5) 
≥65 years 19 (15.8) 11 (9.2) 30 (12.5) 
Sex, n (%)    
Male 70 (58.3) 82 (68.3) 152 (63.3) 
Female 50 (41.7) 38 (31.7) 88 (36.7) 
Race, n (%)    
White 119 (99.2) 117 (97.5) 236 (98.3) 
Black 0 23 1 (0.8) 1 (0.4) 
Asian 1 (0.8) 1 (0.8) 2 (0.8) 
Other 0 23 1 (0.8) 1 (0.4) 
ECOG grade, n (%)    
0 36 (30.0) 32 (26.7) 68 (28.3) 
1 54 (45.0) 62 (51.7) 116 (48.3) 
2 30 (25.0) 25 (20.8) 55 (22.9) 
3 0 (0.0) 1 (0.8) 1 (0.4) 
EIAED use, n (%)    
No 63 (52.5) 65 (54.2) 128 (53.3) 
Yes 57 (47.5) 55 (45.8) 112 (46.7) 
Time since diagnosis, months    
Mean 16.7 19.9 18.3 
SD 15.9 28.6 23.2 
Median 12.0 12.0 12.0 
Range 0-99 3-230 0-230 
Tumor histology at diagnosis,a n 
(%) 
   
Anaplastic astrocytoma 13 (10.8) 14 (11.7) 27 (11.3) 
Glioblastoma  103 (85.8) 98 (81.7) 201 (83.8) 
Gliosarcoma 4 (3.3) 8 (6.7) 12 (5.0) 
Total prior chemotherapy 
treatment regimens, n (%) 
   
1 75 (62.5) 63 (52.5) 138 (57.5) 
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 Imatinib + 
Hydroxyurea Hydroxyurea Total 
Characteristic (n = 120) (n = 120) (N = 240) 
2 37 (30.8) 40 (33.3) 77 (32.1) 
3-4 8 (6.7) 16 (13.3) 24 (10.0) 
>4 0 23 1 (0.8) 1 (0.4) 
Radiotherapy 120 (100.0) 119 (99.2) 239 (99.6) 
Surgeryb 119 (99.2) 120 (100.0) 239 (99.6) 
Reason for surgery    
Curative 76 (63.3) 70 (58.3) 146 (60.8) 
Palliative 51 (42.5) 58 (48.3) 109 (45.4) 
Biopsy 12 (10.0) 23 (19.2) 35 (14.6) 
Unknown 1 (0.8) 0 23 1 (0.8) 
Other 4 (3.3) 4 (3.3) 8 (3.3) 
aTumor histology was not confirmed at time of entry to study. 
bThe outcome of the surgery was not recorded as part of the study data. 
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Table 2. Patient Disposition at Time of Event  
 
Imatinib + 
Hydroxyurea Hydroxyurea Total 
 (n = 120) (n = 120) (N = 240) 
 n (%) n (%) n (%) 
Treatment status    
Randomized to study treatment  120 (100.0) 120 (100.0) 240 (100.0) 
Not exposed to study treatment  2 (1.7) 2 (1.7) 4 (1.7) 
Discontinued study treatmenta 111 (92.5) 104 (86.7) 215 (89.6) 
On treatment at analysis cutoff date 7 (5.8)b 14 (11.7)b 21 (8.8) 
Reason for discontinuation of treatment    
Unsatisfactory therapeutic effect c 25 (20.8) 26 (21.7) 51 (21.3) 
Adverse event(s)c 18 (15.0) 20 (16.7) 38 (15.8) 
Subject withdrew consentc 14 (11.7) 10 (8.3) 24 (10.0) 
Deathc 5 (4.2) 13 (10.8) 18 (7.5) 
Subject's condition no longer requires 
study drugc 5 (4.2) 3 (2.5) 8 (3.3) 
Lost to follow-upc 2 (1.7) 1 (0.8) 3 (1.3) 
Abnormal laboratory value(s) 0 23 2 (1.7) 2 (0.8) 
Protocol violation 0 23 1 (0.8) 1 (0.4) 
Suspected progression and/or ECOG 
grade 3-4 c 44 (36.7) 30 (25.0) 74 (30.8) 
aDiscontinued treatment means that all study therapy (including crossover combination 
therapy following a switch from monotherapy) was discontinued at the cutoff date for 
analysis and includes reports of treatment completion due to suspected progression and/or 
ECOG grade 3-4. 
bPatients had not had an event at analysis cutoff. Following progression, 10 of the 14 
patients from monotherapy switched to combination therapy, resulting in 17 patients on 
combination treatment and 4 on monotherapy. 
cDiscontinuation due to progressive disease could have been captured by any of these. 
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Table 3. PFS Statistics and Tests Based on CIR  
 Imatinib + 
Hydroxyurea Hydroxyurea Total 
 (n = 120) (n = 120 (N = 240) 
Patients with events/censorings, n 111/9 115/5 226/14 
 PD confirmed by MRI assessment 48 55 103 
 PD confirmed by neurologic 
examination but not MRI 
21 16 37 
 PD confirmed only by increased steroid 
use 
24 28 52 
 Death without previous PD 
determination 
18 16 34 
PFS time, weeks     
 25th percentile 5.9 5.1 – 
 50th percentile, median (95% CI) 6.3 (6.1-6.7) 6.1 (6.0-6.7) – 
 75th percentile 12.4 11.7 – 
PFS rates, % (95% CI)    
 6 months 5.3 (1.0-9.7) 6.6 (2.1-11.1) – 
 12 months 2.1 (0.0-5.0) 2.1 (0.0-5.5) – 
Treatment comparison    
Combination versus monotherapy, HR 
(95% CI) 
– – 0.925 
(0.709-
1.206) 
P for HR = 1, unadjusted for the 
sequential nature of the trial 
– – 0.566 
P for HR = 1, adjusted for the 
sequential nature of the trial 
– – 0.564 
Patients alive and without progression were considered to be censored at the time of last 
available visit assessment. 
PFS time percentiles and rates were calculated using the Kaplan-Meier method, ignoring 
strata. 
HR and the associated P value were derived from a Cox proportional hazards model 
stratified for EIAED use (yes, no) and ECOG status (<2, ≥ 2). The hazard ratio indicates the 
effect of combination therapy and monotherapy. An HR <1 favors combination therapy. 
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Table 4. Deaths, Other Serious or Clinically Significant AEs, or Related 
Discontinuations 
  Randomized to Hydroxyurea 










 (n = 118) (n = 118) (n = 118) (n = 85) 
Event n (%) n (%) n (%) n (%) 
Deaths 84 (71.1) 91 (77.1) 27 (22.9) 64 (75.3) 
 Death due to disease 
progression 
76 (64.4) 77 (65.3) 23 (19.5) 54 (63.5) 
SAEs 64 (54.2) 79 (66.9) 46 (39.0) 49 (57.6) 
 NCI/NIH grade 3 or 4 54 (45.8) 64 (54.2) 34 (28.8) 40 (47.1) 
 Suspected to be drug-related 12 (10.2) 12 (10.2) 4 (3.4) 8 (9.4) 
 Leading to dose adjustment 
or interruption 
6 (5.1) 16 (13.6) 9 (7.6) 7 (8.2) 
Leading to permanent 
discontinuation 
9 (7.6) 13 (11.0) 6 (5.1) 7 (8.2) 
AEs 113 (95.8) 113 (95.8) 98 (83.1) 79 (92.9) 
 NCI/NIH grade 3 or 4 79 (66.9) 88 (74.6) 58 (49.2) 51 (60.0) 
 Suspected to be drug-related 75 (63.6) 73 (61.9) 42 (35.6) 51 (60.0) 
 Leading to dose adjustment 
or interruption 
35 (29.7) 41 (34.7) 27 (22.9) 22 (25.9) 
 Leading to permanent 
discontinuation 
19 (16.1) 21 (17.8) 11 (9.3) 10 (11.8) 
All AEs starting after first dose but not later than 28 days after last dose were analyzed. AEs 
were assigned to the treatment group of the patient at the time of onset of the AE.  
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Table 5. Frequent NCI/NIH Grade 3 or 4 AEs by Preferred Term (at Least 5% in 
Any Group)  
  Randomized to Hydroxyurea 












 (n = 118) (n = 118) (n = 118) (n = 85) 
Preferred Term n (%) n (%) n (%) n (%) 
Patients with at least one grade 3 or 4 
AE 
79 (66.9) 88 (74.6) 58 (49.2) 51 (60.0) 
General physical health deterioration 15 (12.7) 15 (12.7) 11 (9.3) 4 (4.7) 
Epilepsy 7 (5.9) 15 (12.7) 8 (6.8) 9 (10.6) 
Leukopenia 8 (6.8) 12 (10.2) 7 (5.9) 8 (9.4) 
Thrombocytopenia 8 (6.8) 11 (9.3) 7 (5.9) 4 (4.7) 
Hemiparesis 7 (5.9) 9 (7.6) 7 (5.9) 2 (2.4) 
Pneumonia 8 (6.8) 8 (6.8) 4 (3.4) 4 (4.7) 
Headache 4 (3.4) 7 (5.9) 5 (4.2) 4 (4.7) 
Intracranial pressure increased 4 (3.4) 6 (5.1) 2 (1.7) 4 (4.7) 
Muscular weakness 7 (5.9) 2 (1.7) 0 2 (2.4) 
Aphasia 8 (6.8) 0 0 0 
Convulsion 2 (1.7) 6 (5.1) 2 (1.7) 4 (4.7) 
All AEs starting after first dose but not later than 28 days after last dose were analyzed. AEs 
were assigned to the treatment given at the time of onset of the AE. A subject with multiple 
occurrences of the same AE was counted only once, at the worst severity of the AE. 
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Figure 1. Study Design 
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Figure 2. Kaplan-Meier Estimates of PFS Using CIR Data   
 
120Imatinib + HU 
Number at risk: 
108  40  33  21  10  8  4  3  3  2  1  1  1  1  1  1  1  1  1  1  0 
120Hydroxyurea 105  44  27  19  12  9  5  3  2  2  2  1  1  1  1  1  1  1  0  0  0 
Imatinib + hydroxyurea = censored 
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Figure 3. Kaplan-Meier Estimates of OS (ITT population)   
 
 
120Imatinib + HU 
Number at risk: 
117 102  85  72  55  40  32  24  19  14  10  9  9  7  5  5  5  5  2  1  0  0
120Hydroxyurea 116 110  90  65  50  40  33  23  19  15  11  9  8  6  6  4  4  2  1  1  1  0
Imatinib + hydroxyurea = censored 
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